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Abstract: Exercise training prevents the onset and the development of many chronic diseases, acting as an 
effective tool both for primary and for secondary prevention. Various mechanisms that may be the effectors 
of these beneficial effects have been proposed during the past decades: some of these are well recognized, 
others less. Muscular myokines, released during and after muscular contraction, have been proposed as key 
mediators of the systemic effects of the exercise. Nevertheless the availability of an impressive amount of 
evidence regarding the systemic effects of muscle-derived factors, few studies have examined key issues: (I) if 
skeletal muscle cells themselves are the main source of cytokine during exercise; (II) if the release of myokines 
into the systemic circulation reach an adequate concentration to provide significant effects in tissues far 
from skeletal muscle; (III) what may be the role carried out by muscular cytokine regarding the well-known 
benefits induced by regular exercise, first of all the anti-inflammatory effect of exercise. Furthermore, 
a greater part of our knowledge regarding myokines derives from the muscle of healthy subjects. This 
knowledge may not necessarily be transferred per se to subjects with chronic diseases implicating a direct or 
indirect muscular dysfunction and/or a chronic state of inflammation with persistent immune-inflammatory 
activation (and therefore increased circulating levels of some cytokines): cachexia, sarcopenia due to multiple 
factors, disability caused by neurological damage, chronic congestive heart failure (CHF) or coronary artery 
disease (CAD). A key point of future studies is to ascertain how is modified the muscular release of myokines 
in different categories of unhealthy subjects, both at baseline and after rehabilitation. The purpose of this 
review is to discuss the main findings on the role of myokines as putative mediators of the therapeutic 
benefits obtained through regular exercise in the context of secondary cardiovascular prevention.
Keywords: Myokines; regular exercise; cardiovascular disease (CVD); cerebrovascular disease; cardiac 
rehabilitation
Submitted May 03, 2017. Accepted for publication Jul 18, 2017.
doi: 10.21037/atm.2017.07.30
View this article at: http://dx.doi.org/10.21037/atm.2017.07.30
Introduction
Regular physical activity protects against several pathologic 
conditions, the main of which are type 2 diabetes, 
cardiovascular diseases (CVD), colon cancer, breast cancer, 
and dementia (1). Recently, it has been proposed that the 
protective effects of physical activity could also be attributed 
to the muscular production of various peptide mediators 
called myokines. Once they are secreted during skeletal 
muscle contraction, they may carry out autocrine, paracrine 
and endocrine activities triggering specific metabolic 
pathways in different tissue and organs far from the muscle 
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such as visceral fat, bone, liver, and nervous system, among 
others (1-4).
Since skeletal muscle represents the most extended 
organ in the human body, the identification of myokines 
is an important finding and may provide a biochemical 
explanation in recognizing molecular mechanisms that 
provide health beneficial effects in chronic disorders 
associated with systemic low-level inflammation (1,5).
Sedentary life has a higher prevalence than that of all 
other cardiovascular modifiable risk factors (6,7). In recent 
times, the profits of regular exercise were extended to 
subjects with established CVD as a treatment option to 
improve the natural history of the disease in secondary 
prevention (8,9). This was a revolutionary changing of view 
because, for a long time, physical rest had been prescribed 
for patients with CVD. 
Numerous biological effects are considered responsible 
for the primary and secondary prevention of CVD and for 
the reduction in the rate of death and inability associated 
with routine exercise. In fact, regular physical activity 
has been demonstrated to reduce abdominal adiposity 
and improve weight control (10-12), reduce triglyceride 
levels, increase high-density lipoprotein (HDL) cholesterol 
levels and decrease low-density lipoprotein (LDL)-to-
HDL ratios (10,13), ameliorate glucose homeostasis and 
insulin sensitivity (14), lower blood pressure (BP) (15,16), 
improve autonomic tone (17,18), balance blood coagulation 
(19,20), augment coronary blood flow (21), improve cardiac 
function (22,23) and enhance endothelial function (24-26). 
Moreover, physical activity seems to play a fundamental 
role in the primary and secondary prevention of CVD 
modulating chronic inflammation as demonstrated by high 
circulating levels of inflammatory mediators that have been 
shown to be directly associated with most of the chronic 
diseases (1,27).
Regular exercise is also associated with improved 
psychological wellness through the reduction of stress, 
anxiety, and depression (10,28,29). Psychological health 
is recognized to be important for the prevention and 
management of CVD.
Finally, findings for the improvements of physical activity 
in the treatment and rehabilitation of subjects with chronic 
CVD should be based on well-designed randomized 
controlled trials (RCTs) (30). Up until now, a large number 
of RCTs studying the therapeutic role of physical activity 
in specific chronic disease has been accomplished allowing 
systematic reviews and meta-analyses. The intent of this 
paper is to analyze, review and discuss the present findings 
on the role of myokines as putative mediators of the 
therapeutic benefits obtained in the main CVD: essential 
hypertension, chronic heart failure (HF), coronary artery 
disease (CAD) and in the cerebrovascular diseases after 
regular physical activity or specific rehabilitation programs.
Myokines expression and secretion by skeletal 
muscle cells 
Many excellent reviews have tried to summarize the 
findings that skeletal muscle represents a secretory organ 
(2,31-34), having the capacity to release hundreds of 
myokines, and the possible clinical implications of this 
evidence. Currently myokines are defined as proteins 
produced by skeletal muscle that are not necessarily induced 
by exercise nor do they have to have a systemic function but 
only work with a paracrine or autocrine mechanism (2,35). 
In order to underline the concept that not all the myokines 
have the same clinical relevance, some authors support 
the alternative definition of “exercise factors”, referring 
to a subgroup of myokines released by skeletal muscle in 
response to exercise and that is secreted into the circulation 
working in a “hormone-like” manner (2,36). For the 
purpose of this review, the list of the myokines potentially 
involved is much more limited, in fact, the greater part 
of the myokines identified to date is the result of the 
secretome analysis over human muscle biopsies collected 
before and after acute exercise (37) often lacking concrete 
confirmations of any clinical effect. The main myokines 
of which we discuss in this review are interleukin (IL)-6, 
IL-8, IL-15, brain-derived neurotrophic factor (BDNF), 
monocyte chemotactic protein 1 (MCP1) and myostatin. 
These are the only molecules which we have enough 
information in unhealthy subjects in the context of cardiac 
rehabilitation and secondary cardiovascular prevention.
It should be underlined that any variation of the gene 
expression of the muscular production and/or of the 
plasmatic release of the myokines after exercise is generally 
dependent on the combination of mode, intensity, and 
duration of exercise (38) and that often is impossible to 
ascertain that a molecule identified as a myokine is of 
exclusive production of skeletal muscle (2).
The prototype myokine, IL-6, seems to be mostly 
responsible for a strong metabolic activity during exercise, 
by ensuring that enough fuel gets to the contracting muscle 
during exercise. Several works during last decades have 
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demonstrated that IL-6 is expressed by both types I and 
II muscle fibers in response to muscle contraction. When 
released by skeletal muscle, IL-6 operates locally to signal 
through gp130Rβ/IL-6Rα, determining the stimulation of 5’ 
adenosine monophosphate-activated protein kinase (AMPK) 
and/or PI3-kinase to enhance glucose uptake and fat 
oxidation. IL-6 may also play an endocrine role to increase 
hepatic glucose synthesis during physical activity or lipolysis 
in adipose tissue (33). IL-6 is greatly generated and released 
after physical activity when circulating insulin levels are 
elevated but, on the other hand, IL-6 has also shown to be 
associated with obesity and decreased insulin action. 
Numerous works found that IL-6 plasma concentration 
is enhanced in patients with unstable angina in comparison 
with those with stable angina or healthy subjects and 
that it may be helpful as a prognostic marker of CVD 
outcome (39), increases the risk of future myocardial 
infarction (40) and has been associated with CVD 
mortality (41). IL-6 also has been supposed to promote 
atherosclerosis by increasing the endothelial synthesis of 
chemokines and adhesion molecules, enhancing endothelial 
dysfunction and stimulating coagulation (42,43). In some 
studies IL-6 is considered as a sensor in the muscle, being 
released when the local glycogen concentration is low. 
It is plausible that a large number of IL-6, derived from 
muscle, reaching the circulation, may act as a hormone 
determining mobilization of extracellular substrates and/or 
to increased substrate delivery during exercise (44). During 
acute physical activity, in addition to high circulating 
concentration of IL-6, other myokines are often detectable 
such as IL-1 receptor antagonist (IL-1 ra), IL-10, soluble 
TNF-receptor (sTNF-R) (with prevalent anti-inflammatory 
properties), IL-8 and IL-15.
A very limited number of papers tried to ascertain 
the effect of regular exercise training on IL-6 levels. In 
patients with chronic HF, regular exercise training is 
reported to decrease the expression of skeletal muscle 
IL-6 mRNA (45), although the basal IL-6 levels of this 
category of patients are higher than healthy age- and 
sex-matched controls. Conflicting results have been 
obtained in subjects with coronary heart disease (CHD), 
comparing IL-6 plasma levels before and after training. 
The skeletal muscle is a major contributor to IL-6 in the 
circulation (46); there is only moderate evidence that regular 
training will decrease plasmatic levels of IL-6 (45,47,48), 
but is reasonable to hypothesize that during acute exercise 
increased levels of IL-6 serve to sustain muscular and not-
muscular metabolism (IL-6 also augments hepatic glucose 
and increases adipose tissue fatty acid release) whereas after 
regular exercise the genomic adaptation to training makes 
less necessary the role of IL-6, whose circulating levels are 
in fact reduced, and in order to avoid the disadvantageous 
effects of a chronic elevation of IL-6, is moreover promoted 
the clearance of this cytokine through the hepatosplanchnic 
blood flow.
IL-15 is a myokine synthesized in human skeletal muscle, and 
has been shown to have an anabolic effect on muscle growth, 
and also to play a role in lipid metabolism (49). Recently, it 
was demonstrated that IL-15 mRNA concentration was 
upregulated in human skeletal muscle following physical 
activity (50), suggesting that IL-15 could reach high levels 
within the muscle after regular exercise. Furthermore, there 
is a negative association between plasma IL-15 levels and fat 
mass (51). 
BDNF is a neurotrophin involved in regulating 
growth and survival of existing neurons (52), and also 
growth and differentiation of new neurons and synapses, 
playing an active role in learning and memory (53-57). 
Various lines of evidence reported low levels of circulating 
BDNF in individuals affected by both obesity and type 2 
diabetes (58) as well as in several chronic neurological 
diseases (Alzheimer’s disease, major depression, impaired 
cognitive function). BDNF mRNA and protein synthesis 
were upregulated in human skeletal muscle after physical 
activity or after electrical stimulation; unfortunately, to date, 
no study has been able to find muscle-derived BDNF into 
the circulation. BDNF appears to be a myokine working 
only with autocrine or paracrine action determining 
powerful effects on peripheral metabolism [for example, fat 
oxidation with a consequent effect on the amount of adipose 
tissue (59)].
MCP1 is a chemokine released into the bloodstream 
from skeletal muscle after specific types of exercise such as 
marathon running or high-duration resistance exercise (60). 
The systemic role in the release of this pro-inflammatory 
mediator after acute high-intensity endurance training is 
debated, being possibly merely linked to an acute skeletal 
muscle injury (61). After chronic training the behavior of 
plasmatic MCP1 is similar to IL-6, IL-8 and other pro-
inflammatory and pro-atherosclerotic mediators: decrease. 
This finding has been reported in various categories 
of unhealthy subjects such as patients with metabolic 
syndrome (62), subjects with chronic HF (63), persons with 
CAD (64).
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Myostatin is a molecule of great interest expressed 
by skeletal muscle because of its potential therapeutic 
role. It is a released ligand of growth and differentiation 
factors belonging to the transforming growth factor 
(TGF) superfamily. Several lines of research suggest that 
myostatin may be involved in the regulation of muscle 
mass (65,66) through its autocrine and paracrine effects 
once it has reached an appropriate concentration into the 
circulation (67). Myostatin has been shown to have a role 
also in the crosstalk between skeletal muscle and adipose 
tissue and may exert an effect on insulin sensitivity (68), 
although it has been recognized to have not a direct 
effect on adipocytes function and metabolism. However, 
an enhanced concentration of myostatin in muscle mass 
provokes to a higher energy amount, increased lipid 
uptake, and more active metabolism, reducing the volume 
of adipose tissue (69). Myostatin, acting as a key regulator 
of skeletal muscle mass, is elevated in advanced stages 
of chronic HF, possibly acting as a mediator of cardiac 
cachexia. Lenk et al. reported that 12 weeks of exercise 
training may induce a significant reduction of myostatin 
in skeletal muscle, demonstrating the reversibility of 
the muscle wasting in chronic HF (70). Higher levels of 
myostatin than controls have been found also in patients 
with chronic diseases associated with decreased mobility, 
inflammation, and weight loss such as chronic obstructive 
pulmonary disease (COPD) (71,72) or end-stage chronic 
kidney disease (CKD) undergoing to hemodialysis (73).
The list of myokines is steadily increasing over the 
years; several of which potentially of interest. Fibroblast 
growth factor (FGF)-21, is a member of the FGF family 
involved in carbohydrate and lipid homeostasis that seems 
to be associated with obesity, diabetes and atherosclerotic 
damage (74,75). 
Apelin, is an interesting insulin-related factor localized 
in cardiomyocytes and vascular cells that seem to play a key 
role in the regulation of vascular tone and cardiovascular 
function (76,77).
Follistatin like-1(FSTL1) is a glycoprotein that has been 
associated with an improved vascular health and function, 
counteracting endothelial dysfunction (78). 
The finding that skeletal muscle during contraction 
expresses and releases many myokines in the circulation 
suggests a relationship between myokines and metabolism 
both in physiologic and in pathologic conditions. Since 
circulating markers of inflammation are chronically elevated 
in CVD and other vascular diseases, a change in their levels 
induced through physical activity may play a role in the 
treatment of these diseases; in the second part of this review, 
we tried to discuss this issue, referring to the main vascular 
pathologic conditions.
Arterial hypertension
The main guidelines indicate that routine exercise is 
considered to play a fundamental role in the prevention 
and treatment of hypertension (79). Several studies 
demonstrated that exercise is associated with a lower BP, 
and meta-analyses of RCTs have indicated that chronic 
dynamic aerobic endurance training can be effective to 
reduce BP levels both in normotensives and in hypertensive 
subjects (16,80-83). A recent meta-analysis (84) examines 
the effect of regular dynamic aerobic endurance exercise on 
resting and ambulatory BP, on BP-regulating mechanisms, 
and on concomitant cardiovascular risk factors, like body 
fatness, waist circumference, blood lipids, and glucose/
insulin dynamics, finding beneficial effects of exercise in all 
outcomes and concomitant risk factors. They recognized 
that the BP decline was most evident in the hypertensive 
study groups, but a good BP reduction may also be found 
in normotensive and pre-hypertensive subjects (85). A 
reduction in the activity of the autonomic nervous system is 
supposed to be involved in the decrease of BP after exercise, 
as demonstrated by the 29% lower plasma norepinephrine 
levels in trained subjects when compared with unfit 
counterparts. Interestingly, some studies recognized a lack 
of an effect on BP during sleep (86), when sympathetic 
activity is reduced, that may be compatible with the 
hypotensive effect of the sympathetic nervous system after 
regular exercise. The 20% decrease of plasma renin activity 
suggests the role of the renin-angiotensin system (87,88). 
Moreover, the decreased level of plasma renin activity 
supports the hypothesis that the reduction in the activity 
of the sympathetic nervous system also affects the kidney, 
which is the most potent factor involved in long-term BP 
regulation (89). Another import role in the exercise-induced 
reduction of BP levels is played also by the consequent 
reduction of insulin resistance and improvement of the 
endothelial function obtained through regular training (1).
Other studies conducted with untreated patients 
with mild essential hypertension who walked quickly for 
30 minutes 5 to 7 times per week for 12 weeks found a 
reduction in systolic and diastolic BPs and an augmented 
forearm blood flow in response to acetylcholine infusion. 
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This increased blood flow seems blocked by a nitric oxide 
(NO) inhibitor (90), suggesting a role for NO. Sedentary 
hypertensive rats seem to have augmented adrenergic 
agent-induced vasoconstricting responses, associated with 
reduced NO expression, of thoracic aortas and carotid 
arteries compared with exercise-trained hypertensive 
rats (91). Moreover, plasma nitrate (an index of NO 
quantity) was decreased in sedentary hypertensive rats 
compared with allowed access to 35 days of voluntary wheel 
running (92). Interestingly, this effect persists for 36 h, but 
exercised rats returned to sedentary levels by the 7th day of 
detraining. 
The most validated mechanism supposed to lower BP 
through physical activity contemplates the synergism of 
both vascular and neurohumoral systems that determine a 
reduction in total peripheral resistance and catecholamines 
level (93). A comprehensive study of the benefits that 
exercise exerts on BP is very complicated since physical 
activity is involved in many other different effects like lipid and 
glucose control, weight loss, improved endothelial function 
and enhanced antioxidant capacity. Some data suggest that 
a genetic link is present between the grade of BP reduction 
and acute and chronic exercise in accord to the variability of 
results in individuals that was encountered (94). Moreover, 
angiotensin-converting enzyme (ACE), apolipoprotein 
E (apoE), and lipoprotein lipase (LPL) genotypes can be 
found in hypertensive subjects whose BP and cardiovascular 
risk can be markedly reduced with regular exercise. These 
genotype-dependent responses can support the hypothesis 
that endurance physical activity can lead to a more 
significant improvement of BP and circulating lipid levels 
in genetically advantaged subjects. Despite this significant 
amount of evidence supporting the role of regular exercise 
in improving the BP profile both in normotensive and in 
hypertensive subjects, to date no studies addressed the issue 
of the possible role carried out by myokines in causing these 
beneficial effects. Future studies are needed to clarify this 
topic.
Cerebrovascular disease
Neuroinflammation represents a key mechanism during 
both the acute phase of an ischemic stroke and in the 
recovery phase during the post-stroke rehabilitation. The 
level of systemic inflammation in stroke patients strongly 
depends on the diagnostic subtype of stroke and is directly 
related to the extent of the neurological damage during 
the acute phase and to the residual disability (95-101). 
Following neurological rehabilitation, usually initiated 
early as possible after the clinical stabilization, various 
authors demonstrated the change of plasma concentrations 
of different circulating mediators, whose role is under 
investigation. An increase of the plasmatic levels of the most 
famous neurotrophic factor, BDNF, has been demonstrated 
after acute aerobic exercise in an intensity-dependent 
manner both in healthy subjects (102,103) and in multiple 
sclerosis patients (104). The main origin of exercise-induced 
circulating BDNF is likely to be the brain rather than 
the muscle (specific areas of the human brain such as the 
hippocampus and cerebral cortex) (103,105). Nevertheless 
with the uncertainty regarding the main source, exercise-
induced BDNF may be reasonably considered as an 
effective mediator of improved neurological health.
Another recently discovered factor associated with 
exercise-induced neuronal recovery after ischemic injury is 
the insulin growth factor (IGF)-1. Various reports indicate 
that IGF-1, released by various tissues including the skeletal 
muscle, may have a relevant role in neuroplasticity together 
with BDNF (106-108). IGF-1 would play an active role 
in mediating the recovery of neuronal function through 
the rehabilitation, despite an excessive release of IGF-1 is 
reported to have opposite effects, inducing an increased 
level of neuroinflammation and a worst outcome (109).
Other putative myokines having a certain neurotrophic 
activity are various molecules belonging to the family of 
the neurotrophins (110), the vascular endothelial growth 
factor (VEGF) (111), the neurotrophin ciliary neurotrophic 
factor (CNTF) (112), FGF21 (113), even if any significant 
muscular release of these substances after acute exercise or 
exercise training is far from being proven.
Congestive HF 
Physical inactivity seems to play a role in the development 
of a great percentage of cases of congestive heart failure 
(CHF) and also aggravate conditions associated with 
previously diagnosed CHF patients. A sedentary lifestyle 
can account for 9.2% of all cases of CHF. Physical activity 
of individuals affected by moderate to severe CHF can 
reduce all-cause mortality by 63% and decreased hospital 
readmission for HF by 71% (114). Moreover, subjects 
with CHF improved their quality of life from participating 
in physical training programs (115). According to 14 
RCTs, physical activity showed a physiological favorable 
effect in CHF patients focusing on short-term training 
program benefits (116). In the Cochrane systematic 
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review of exercise-based interventions for HF (117), the 
authors concluded that physical activity clearly ameliorates 
short-term exercise capacity. The meta-analysis by the 
ExTraMATCH Collaborative Group (118) found that there 
was no evidence that supervised exercise training programs 
for CHF patients were dangerous and indeed authors 
encountered an overall reduction in mortality. 
Even if the principal affected organ in CHF is recognized 
to be the heart, skeletal muscle is thought to be a secondary 
defective organ involved in reducing exercise tolerance. 
Moreover, skeletal muscle dysfunction in CHF experiments 
great benefits with regular physical training, even if the 
function of the heart remains unaffected by exercise. 
In many HF subjects, the limitation in skeletal muscle 
function is more predominant than the hemodynamic 
impairment due to the cardiac dysfunction (119). In these 
patients the reduction of the functional capacity may lead 
to a progressive reduction of the mobility; this condition 
has shown to increase the risk of appearance of other 
chronic diseases. The worsening of the health status due 
to the multiple comorbidities causes further exercise 
restriction and increased hospitalization and mortality in 
individuals with symptomatic HF (119). It is recognized 
that the reductions in physical capacity in CHF are not just 
secondary to alterations in myocardial function (120). In 
fact, some indexes of cardiac function like ejection fraction 
are not improved by exercise in CHF patients (121). On 
the other hand, exercise capacity does correlate greatly with 
measures of peripheral muscular strength and endurance 
which explain the exercise intolerance in CHF patients with 
cellular alterations in the periphery (122). An interesting 
study (123) showed that 4–6 months of aerobic training 
in CHF subjects ameliorate exercise capacity and increase 
blood flow to the peripheral musculature. These muscular 
changes are accompanied by a decreased skeletal muscle 
expression of tumor necrosis factor -alpha, IL-1-beta, 
and IL-6 (45), with the following reduction of systemic 
inflammation in these patients. 
The precise mechanisms through which regular physical 
activity determines its positive effect in patients with HF 
remains not completely clear. Certainly, the significant 
clinical improvement obtained through the regular training 
in CHF patients is the result of a complex interplay of 
different effects:
(I) Improved cardiopulmonary efficiency and 
pulmonary functional capacity (124); 
(II) Amelioration of myocardial perfusion in ischemic 
subjects by reducing endothelial dysfunction 
and by inducing new vessel formation by way of 
intermittent ischemia (118); 
(III) Improved myocardial contractility and diastolic 
filling (125); 
(IV) Counteract the muscle wasting and cachexia. 
Myostatin may be involved in the pathophysiology 
of cardiac progressive dysfunction in chronic 
HF. In the already cited study of Lenk et al. (70), 
chronic HF subjects at baseline showed a two-
fold increase of myostatin mRNA (P= 0.05) and 
a 1.7-fold (P= 0.01) augmentation of protein 
content in skeletal muscle compared to healthy 
subjects. Also in animal models, myostatin seems 
to be involved: myocardial gene and protein 
expression are increased in response to chronic 
volume overload-induced by aortocaval shunt in 
rats (126) and after acute myocardial infarction 
in rat cardiomyocytes (127); 
(V) Reduction of the systemic inflammation;
(VI) Attenuation of the sympathoexcitation, a typical 
feature of CHF, helping to restore autonomic 
balance to the heart even in the persistence of 
cardiac dysfunction (128);
(VII) Modulation of the cardiac angiotensin receptor, 
with a secondary restoration of the overactivated 
renin-angiotensin-aldosterone system (129). 
CAD 
Many interesting papers have suggested a positive effect of 
physical activity on coronary vasodilation and endothelial 
function. Animal studies have largely demonstrated that 
physical activity determines a flow-mediated epicardial 
coronary vasodilation that seems to be dependent upon the 
integrity of the endothelium (130,131). 
As we have already discussed, hypertension seems to be 
associated with decreased expression and/or augmented 
degradation of vascular NO (132), causing a reduction in 
vessel vasodilation. The altered availability of vascular NO, 
expression of endothelial dysfunction, is also involved in 
the progress of atherosclerosis. Physical activity increases 
NO expression in endothelial cells (21,133). Vasodilation 
secondary to exercise training is supposed to be mediated 
by shear stress (134). In fact, when in studies where fluid 
flow was increased in culture, endothelial cells register 
an augmentation of NOS mRNA (135). The augmented 
levels of NO stimulate vasodilation, which then lessens the 
enhancing in shear stress across an endothelial cell. 
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Numerous systematic reviews have shown the fundamental 
role played by regular training to attenuate or reverse 
the disease process in patients with CAD. For instance, a 
systematic review and meta-analysis involving 48 clinical 
trials (136) indicated that, compared with usual care, cardiac 
rehabilitation determine a marked reduction of incidence 
of premature death from any cause and from CVD in 
particular. In another systematic review, RCTs show that 
physical activity in documented CHD decrease all-cause 
mortality by 27% and total cardiac mortality by 31%, but 
not the rate of non-fatal myocardial infarction (9).
Milani et al. conducted the first studies elucidating the 
benefits of physical activity and cardiovascular rehabilitation 
on the plasma levels of C-reactive protein (CRP). They 
encountered a great reduction in CRP after the 3-month 
intervention in CAD patients with and without metabolic 
syndrome (137), in weight gainers and losers (138), and 
in subjects with or without statin therapy (138). These 
findings were confirmed by other studies (139-141). An 
important study (142), assessing the results of aerobic 
exercise training on concentrations of pro- and anti-
inflammatory cytokines, IL-1, IL-6, IL-10, INF-gamma, 
and CRP in CAD subjects attending a cardiac rehabilitation 
program demonstrated a consistent reduction of CRP levels 
after 12 weeks of training, along with a significant decrease 
of all pro-inflammatory cytokines, IL-1, IL-6, interferon-
gamma and a great increase in the main anti-inflammatory 
cytokine: IL-10 (142). In another study (140) after 
24 months of exercise, CRP concentration was reduced by 
41% and IL-6 levels by 18 % but no change was observed 
in the percutaneous intervention group. Furthermore, these 
findings indicate that cardiac rehabilitation and physical 
activity exert an anti-inflammatory effect independent 
of statin therapy and weight loss. Similarly, in patients 
with CAD, 6 months of routine exercise showed an 
important decrease of IL-6 and other pro-inflammatory 
cytokines (143). Conversely, Astengo et al. in 62 individuals 
with stable angina followed for 8 months before and after 
the intervention of percutaneous coronary intervention 
(PCI) with a training program that consisted of home-
based training on a bicycle ergometer did not find 
any modifications of plasmatic concentration of pro-
inflammatory or anti-inflammatory cytokines (IL-6, IL-8, 
and IL-10) (144). Niessner et al. (64) evaluated the benefits 
of endurance exercise on atherosclerosis inflammatory 
markers in patients with CAD and cardiovascular risk 
factors. In this study, after a training intervention period 
of 12 weeks, authors encountered a great reduction of the 
chemokines IL-8, monocyte chemoattractant protein-1 
and of matrix metalloproteinase-9 (MMP-9), that markedly 
reduced after training, but an insignificant modification of 
IL-6 and hsCRP (64). These results also indirectly confirm 
the improved stabilization of the atherosclerotic plaque 
induced by regular exercise and provide an explanation for 
the reduced rate of vascular event exercise-related.
In a study examining 86 cardiac surgery patients after 
15 days of cardiovascular rehabilitation authors encountered 
a significant reduction of baseline concentration of 
IL-8 (145), moreover 15 weeks of exercise training decreased 
IL-8 plasmatic levels in 27 obese subjects (146) and 12 weeks 
of controlled endurance exercise lowered IL-8 concentration 
in individuals with CAD and multiple cardiovascular risk 
factors (64). 
The overall effect observed after cardiac rehabilitation 
in CHD patients seems to be a reduction of the main 
circulating cytokines associated with chronic inflammation. 
In relation to the other main myokines discussed in this 
review, a higher serum level of myostatin has been related 
to lower muscle function, given the fact that myostatin 
acts as a negative regulator of muscular growth. In 
experimental models of myocardial ischemia-related injury, 
it has been reported an immediate upregulation of cardiac 
myostatin (147). This finding allows us to hypothesize both 
an active role of this molecule in the ischemia-induced 
myocardial damage and a putative role for the inhibitors of 
myostatin (i.e., follistatin) induced by exercise in mediating 
the recovery after an acute episode of CHD.
Conclusive remarks
Everyone agreed on having to advise routine exercise 
among individuals with CVD; several lines of research 
confirm the significant benefits associated with an improved 
physical fitness without causing adverse effects on disease 
progression. Work on subjects with CAD as well as studies 
on individuals with CHF show that physical activity is 
associated with lower all-cause mortality compared with 
controls. Among old patients with CVD, both enhanced 
fitness levels and a decrease in disease-related symptoms are 
very important effects although several RCTs are too short 
to document differences in the true disease progression 
between groups. Although recommended characteristics of 
a training program ameliorating aerobic fitness are known 
to include at least 20 minutes of moderate-intensity training 
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twice a week or more during at least 6 weeks in accord to 
American College of Sports Medicine, in older patients 
with CVD there is a need of more tailored programs with 
a specific intensity of exercise. Low-intensity regimens are 
effective as high-intensity programs in different pathologic 
conditions such as type 2 diabetes (14) and 5 to 10 minutes 
of running/day also at slow speed (<6 miles/hour) has 
been associated with markedly reduced risk of death from 
all causes and CVD (148), while 92 minutes per week or 
15 minutes a day of moderate intensity endurance training 
have been reported to provide a 14% reduced risk of all-
cause mortality and 3 years longer life expectancy (149). 
But, on the other hand, several lines of evidence indicate 
that seems to be a threshold to the dose/effectiveness curve 
of exercise benefit: to stay on the safe side, the progression 
of exercise programs must be slow and tailored considering 
patients’ ability and occurrence of different symptoms. Most 
of the patients seem to have a positive effect from low- to 
moderate-intensity exercise training. However, according to 
the available RCTs, final comprehensive conclusions about 
the kind of training or dose-response of exercise therapy in 
the treatment of CVD cannot be finally assessed. 
The mechanisms through which regular exercise 
is of benefit for these categories of subjects are only 
partly understood. Improved overall control of the main 
cardiovascular risk factors, enhanced NO-mediated 
vasodilation and optimized shear stress are surely main 
benefits. Myokines exert various endocrine effects on 
various tissues and organs, including adipose tissue, the 
liver, the pancreas and the brain; mainly exerting a certain 
metabolic role. Acute exercise and regular training exert 
very different effects on muscular myokinome, with acute 
exercise eliciting a more stress-like response compared with 
a chronic adaptive response observed after habitual exercise. 
To date, conclusive evidence is lacking regarding a possible 
role exerted by myokines released into the bloodstream 
after exercise and acting in a hormone-like manner as 
mediators of the beneficial effects of exercise in patients 
in secondary prevention after a vascular event. Other 
well-known hemodynamic, immunomodulatory and anti-
atherosclerotic effects of regular exercise are convincingly 
able to explain the epidemiologic data showed in this review. 
But nevertheless, molecules such as myostatin, FGF21 
(150,151), apelin, and FSTL1 (152), to name just a few, are 
promising therapeutic agent of absolute interest. We are 
expecting ad hoc trials clarifying their real potential. 
Regarding the putative anti-inflammatory effect of 
exercise, confirmed by several lines of evidence, a conclusive 
message may be similar: the expression of myokines from 
skeletal muscle is directly related to training intensity, 
while the anti-inflammatory effect of exercise is not. It is 
largely accepted that the expression of IL-6 after acute 
physical activity do not reach consistent concentrations 
with short durations or low-to-moderate intensity of 
training (153) and that routine physical activity determines 
a decrease of IL-6 levels (instead of IL-10 concentration 
that is shown to increase). On the other hand, many studies 
reported data that assess how also low-intensity programs 
of exercise, such as fast walking (16,27,154,155), could 
produce a consistent decrease in plasma markers of systemic 
inflammation although does not determine any enhance 
in circulating cytokines expression (156). These data allow 
us to hypothesize that other well-known mechanisms 
(direct and indirect modulation of the activity of immune 
cells, neuroendocrine changes induced by exercise, 
reduced fat mass, for example) could explain a great part 
of the anti-inflammatory effect of exercise. Moreover, in 
clinical practice, physical activity is not prescribed alone 
but rather with other lifestyle advice such as weight loss, 
low-fat diet, smoking cessation or also in combination 
with pharmacological treatments. How may coexisting 
treatments influence skeletal muscle myokines expression? 
Is there any synergic effect between drugs and exercise? 
Well-designed cross-sectional and longitudinal studies are 
needed to better explain the potentiality of exercise in the 




Conflicts of Interest: The authors have no conflicts of interest 
to declare.
References
1. Di Raimondo D, Musiari G, Miceli G, et al. Preventive 
and Therapeutic Role of Muscle Contraction Against 
Chronic Diseases. Curr Pharm Des 2016;22:4686-99. 
2. Di Raimondo D, Tuttolomondo A, Musiari G, et al. Are 
the Myokines the Mediators of Physical Activity-Induced 
Health Benefits? Curr Pharm Des 2016;22:3622-47. 
Annals of Translational Medicine, Vol 5, No 15 August 2017 Page 9 of 14
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2017;5(15):300atm.amegroups.com
3. Brandt C, Pedersen BK. The role of exercise-induced 
myokines in muscle homeostasis and the defense against 
chronic diseases. J Biomed Biotechnol 2010;2010:520258
4. Peake JM, Della Gatta P, Suzuki K, et al. Cytokine 
expression and secretion by skeletal muscle cells: regulatory 
mechanisms and exercise effects. Exerc Immunol Rev 
2015;21:8-25. 
5. Pinto A, Di Raimondo D, Tuttolomondo A, et al. 
Effects of physical exercise on inflammatory markers of 
atherosclerosis. Curr Pharm Des 2012;18:4326-49. 
6. Blair SN, Brodney S. Effects of physical inactivity and 
obesity on morbidity and mortality: current evidence and 
research issues. Med Sci Sports Exerc 1999;31:S646-62. 
7. Blair SN, Cheng Y, Holder JS. Is physical activity or 
physical fitness more important in defining health benefits? 
Med Sci Sports Exerc 2001;33:S379-99. 
8. Wannamethee SG, Shaper AG, Walker M. Physical 
activity and mortality in older men with diagnosed 
coronary heart disease. Circulation 2000;102:1358-63. 
9. Jolliffe JA, Rees K, Taylor RS, et al. Exercise-based 
rehabilitation for coronary heart disease. Cochrane 
Database Syst Rev 2001;(1):CD001800. 
10. Warburton DE, Gledhill N, Quinney A. Musculoskeletal 
fitness and health. Can J Appl Physiol 2001;26:217-37. 
11. Seidell JC, Cigolini M, Deslypere JP, et al. Body fat 
distribution in relation to physical activity and smoking 
habits in 38-year-old European men. The European Fat 
Distribution Study. Am J Epidemiol 1991;133:257-65. 
12. Tremblay A, Despres JP, Leblanc C, et al. Effect of 
intensity of physical activity on body fatness and fat 
distribution. Am J Clin Nutr 1990;51:153-7. 
13. Berg A, Halle M, Franz I, et al. Physical activity and 
lipoprotein metabolism: epidemiological evidence and 
clinical trials. Eur J Med Res 1997;2:259-64 
14. Balducci S, Zanuso S, Cardelli P, et al. Effect of high- 
versus low-intensity supervised aerobic and resistance 
training on modifiable cardiovascular risk factors in type 2 
diabetes; the Italian Diabetes and Exercise Study (IDES). 
PLoS One 2012;7:e49297 
15. Di Raimondo D, Miceli G, Casuccio A, et al. Does 
sympathetic overactivation feature all hypertensives? 
Differences of sympathovagal balance according to 
night/day blood pressure ratio in patients with essential 
hypertension. Hypertens Res 2016;39:440-8. 
16. Pinto A, Di Raimondo D, Tuttolomondo A, et al. Twenty-
four hour ambulatory blood pressure monitoring to 
evaluate effects on blood pressure of physical activity in 
hypertensive patients. Clin J Sport Med 2006;16:238-43. 
17. Adamopoulos S, Piepoli M, McCance A, et al. Comparison 
of different methods for assessing sympathovagal balance 
in chronic congestive heart failure secondary to coronary 
artery disease. Am J Cardiol 1992;70:1576-82. 
18. Tiukinhoy S, Beohar N, Hsie M. Improvement in heart 
rate recovery after cardiac rehabilitation. J Cardiopulm 
Rehabil 2003;23:84-7. 
19. Physical activity and cardiovascular health. NIH 
Consensus Development Panel on Physical Activity and 
Cardiovascular Health. JAMA 1996;276:241-6. 
20. Rauramaa R, Salonen JT, Seppanen K, et al. Inhibition 
of platelet aggregability by moderate-intensity physical 
exercise: a randomized clinical trial in overweight men. 
Circulation 1986;74:939-44. 
21. Hambrecht R, Wolf A, Gielen S, et al. Effect of exercise 
on coronary endothelial function in patients with coronary 
artery disease. N Engl J Med 2000;342:454-60. 
22. Warburton DE, Gledhill N, Jamnik V, et al. Induced 
hypervolemia, cardiac function, VO2max and performance 
of elite cyclists. Med Sci Sports Exerc 1999;31:800-8. 
23. Warburton DE, Haykowsky MJ, Quinney HA, et al. 
Blood volume expansion and cardiorespiratory function: 
effects of training modality. Med Sci Sports Exerc 
2004;36:991-1000. 
24. Gokce N, Vita JA, Bader DS, et al. Effect of exercise on 
upper and lower extremity endothelial function in patients 
with coronary artery disease. Am J Cardiol 2002;90:124-7. 
25. Kobayashi N, Tsuruya Y, Iwasawa T, et al. Exercise 
training in patients with chronic heart failure improves 
endothelial function predominantly in the trained 
extremities. Circ J 2003;67:505-10. 
26. Hambrecht R, Gielen S, Linke A, et al. Effects of exercise 
training on left ventricular function and peripheral 
resistance in patients with chronic heart failure: a 
randomized trial. JAMA 2000;283:3095-101 
27. Di Raimondo D, Tuttolomondo A, Buttà C, et al. 
Metabolic and anti-inflammatory effects of a home-based 
programme of aerobic physical exercise. Int J Clin Pract 
2013;67:1247-53. 
28. Dunn AL, Trivedi MH, O’Neal HA. Physical activity 
dose–response effects on outcomes of depression and 
anxiety. Med Sci Sports Exerc 2001;33:S587-97. 
29. Pareja-Galeano H, Mayero S, Perales M, et al. Biological 
Rationale for Regular Physical Exercise as an Effective 
Intervention for the Prevention and Treatment of 
Depressive Disorders. Curr Pharm Des 2016;22:3764-75. 
30. Kujala UM. Evidence for exercise therapy in the treatment 
of chronic disease based on at least three randomized 
Di Raimondo et al. Myokines and cardiac rehabilitation
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2017;5(15):300atm.amegroups.com
Page 10 of 14
controlled trials – summary of published systematic 
reviews. Scand J Med Sci Sports 2004:14:339-45. 
31. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: 
skeletal muscle as a secretory organ. Nat Rev Endocrinol 
2012;8:457-65. 
32. Raschke S, Eckel J. Adipo-myokines: two sides of the same 
coin-mediators of inflammation and mediators of exercise. 
Mediators Inflamm 2013;2013:320724.
33. Pedersen BK, Febbraio MA. Muscle as an endocrine 
organ: focus on muscle-derived interleukin-6. Physiol Rev 
2008;88:1379-406. 
34. Welc SS, Clanton TL. The regulation of interleukin-6 
implicates skeletal muscle as an integrative stress sensor 
and endocrine organ. Exp Physiol 2013;98:359-71. 
35. Henningsen J, Rigbolt KT, Blagoev B, et al. Dynamics 
of the skeletal muscle secretome during myoblast 
differentiation. Mol Cell Proteomics 2010;9:2482-96. 
36. Catoire M, Kersten S. The search for exercise factors in 
humans. FASEB J 2015;29:1615-28. 
37. Catoire M, Mensink M, Kalkhoven E, et al. Identification 
of human exercise-induced myokines using secretome 
analysis. Physiol. Genomics 2014;46:256-67. 
38. Nieman DC, Konrad M, Henson DA, et al. Variance in 
the acute inflammatory response to prolonged cycling 
is linked to exercise intensity. J Interferon Cytokine Res 
2012;32:12-7. 
39. Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of 
interleukin-6 in unstable angina. Circulation 1996;94:874-7. 
40. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma 
concentration of interleukin-6 and the risk of future 
myocardial infarction among apparently healthy men. 
Circulation 2000;101:1767-72. 
41. Harris TB, Ferrucci L, Tracy RP, et al. Associations of 
elevated interleukin-6 and C-reactive protein levels with 
mortality in the elderly. Am J Med 1999;106:506-12. 
42. Yudkin JS, Kumari M, Humphries SE, et al. Inflammation, 
obesity, stress and coronary heart disease: is interleukin-6 
the link? Atherosclerosis 2000;148:209-14. 
43. Elhage R, Clamens S, Besnard S, et al. Involvement 
of interleukin-6 in atherosclerosis but not in the 
prevention of fatty streak formation by 17beta-estradiol 
in apolipoprotein E-deficient mice. Atherosclerosis 
2001;156:315-20. 
44. Keller C, Steensberg A, Pilegaard H, et al. Transcriptional 
activation of the IL-6 gene in human contracting skeletal 
muscle: influence of muscle glycogen content. FASEB J 
2001;15:2748-50. 
45. Gielen S, Adams V, Mobius-Winkler S, et al. Anti-
inflammatory effects of exercise training in the skeletal 
muscle of patients with chronic heart failure. J Am Coll 
Cardiol 2003;42:861-8. 
46. Steensberg A, Van Hall G, Osada T, et al. Production 
of interleukin-6 in contracting human skeletal muscles 
can account for the exercise-induced increase in plasma 
interleukin-6. J Physiol 2000;529:237-42. 
47. Palmefors H, DuttaRoy S, Rundqvist B, et al. The 
effect of physical activity or exercise on key biomarkers 
in atherosclerosis--a systematic review. Atherosclerosis 
2014;235:150-61. 
48. Kadoglou NP, Perrea D, Iliadis F, et al. Exercise reduces 
resistin and inflammatory cytokines in patients with type 2 
diabetes. Diabetes Care 2007;30:719-21. 
49. Nielsen AR, Pedersen BK. The biological roles of exercise-
induced cytokines: IL-6, IL-8, and IL-15. Appl Physiol 
Nutr Metab 2007;32:833-9. 
50. Nielsen AR, Mounier R, Plomgaard P, et al. Expression 
of interleukin-15 in human skeletal muscle effect of 
exercise and muscle fibre type composition. J Physiol 
2007;584:305-12. 
51. Nielsen AR, Hojman P, Erikstrup C, et al. Association 
between interleukin-15 and obesity: interleukin-15 as a 
potential regulator of fat mass. J Clin Endocrinol Metab 
2008;93:4486-93. 
52. Mattson MP, Maudsley S, Martin B. BDNF and 
5-HT: a dynamic duo in age-related neuronal plasticity 
and neurodegenerative disorders. Trends Neurosci 
2004;27:589-94. 
53. Tyler WJ, Alonso M, Bramham CR, et al. From acquisition 
to consolidation: on the role of brain-derived neurotrophic 
factor signaling in hippocampal-dependent learning. Learn 
Mem 2002;9:224-37. 
54. Laske C, Stransky E, Leyhe T, et al. Stage-dependent 
BDNF serum concentrations in Alzheimer's disease. J 
Neural Transm (Vienna) 2006;113:1217-24. 
55. Karege F, Perret G, Bondolfi G, et al. Decreased serum 
brain-derived neurotrophic factor levels in major depressed 
patients. Psychiatry Res 2002;109:143-8. 
56. Komulainen P, Pedersen M, Hänninen T, et al. BDNF 
is a novel marker of cognitive function in ageing 
women: the DR’s EXTRA Study. Neurobiol Learn Mem 
2008;90:596-603. 
57. Krabbe KS, Mortensen EL, Avlund K, et al. Brain-derived 
neurotrophic factor predicts mortality risk in older women. 
J Am Geriatr Soc 2009;57:1447-52. 
58. Krabbe KS, Nielsen AR, Krogh-Madsen R, et al. Brain-
derived neurotrophic factor (BDNF) and type 2 diabetes. 
Annals of Translational Medicine, Vol 5, No 15 August 2017 Page 11 of 14
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2017;5(15):300atm.amegroups.com
Diabetologia 2007;50:431-8. 
59. Pedersen BK, Pedersen M, Krabbe KS, et al. Role of 
exercise-induced brain-derived neurotrophic factor 
production in the regulation of energy homeostasis in 
mammals. Exp Physiol 2009;94:1153-60. 
60. Mathers JL, Farnfield MM, Garnham AP, et al. Early 
inflammatory and myogenic responses to resistance 
exercise in the elderly. Muscle Nerve 2012;46:407-12. 
61. Pillon NJ, Bilan PJ, Fink LN, et al. Cross-talk between 
skeletal muscle and immune cells: muscle-derived 
mediators and metabolic implications. Am J Physiol 
Endocrinol Metab 2013;304:E453–E65. 
62. Roberts CK, Won D, Pruthi S, et al. Effect of a short-
term diet and exercise intervention on oxidative stress, 
inflammation, MMP-9, and monocyte chemotactic activity 
in men with metabolic syndrome factors. J Appl Physiol 
(1985) 2006;100:1657-65.
63. Adamopoulos S, Parissis J, Kroupis C, et al. Physical 
training reduces peripheral markers of inflammation 
in patients with chronic heart failure. Eur Heart J 
2001;22:791-7.
64. Niessner A, Richter B, Penka M, et al. Endurance training 
reduces circulating inflammatory markers in persons at 
risk of coronary events: impact on plaque stabilization? 
Atherosclerosis 2006;186:160-5.
65. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal 
muscle mass in mice by a new TGF-beta superfamily 
member. Nature 1997;387:83-90. 
66. Lee SJ, McPherron AC. Regulation of myostatin 
activity and muscle growth. Proc Natl Acad Sci USA 
2001;98:9306-11. 
67. Elliott B, Renshaw D, Getting S, et al. The central role of 
myostatin in skeletal muscle and whole body homeostasis. 
Acta Physiol (Oxf) 2012;205:324-40. 
68. Argilés JM, Orpí M, Busquets S, et al. Myostatin:more 
than just a regulator of muscle mass. Drug Discov Today 
2012;17:702-9. 
69. Allen DL, Hittel DS, McPherron AC. Expression and 
function of myostatin in obesity, diabetes, and exercise 
adaptation. Med Sci Sports Exerc 2011;43:1828-35. 
70. Lenk K, Erbs S, Höllriegel R, et al. Exercise training leads 
to a reduction of elevated myostatin levels in patients with 
chronic heart failure. Eur J Prev Cardiol 2012;19:404-11. 
71. Ju CR, Chen RC. Serum myostatin levels and skeletal 
muscle wasting in chronic obstructive pulmonary disease. 
Respir Med 2012;106:102-8. 
72. Remels AH, Gosker HR, Langen RC, et al. The 
mechanisms of cachexia underlying muscle dysfunction in 
COPD. J Appl Physiol (1985) 2013;114:1253-62. 
73. Han DS, Chen YM, Lin SY, et al. Serum myostatin 
levels and grip strength in normal subjects and patients 
on maintenance haemodialysis. Clin Endocrinol (Oxf) 
2011;75:857-63. 
74. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, et 
al. Circulating fibroblast growth factor-21 is elevated 
in impaired glucose tolerance and type 2 diabetes and 
correlates with muscle and hepatic insulin resistance. 
Diabetes Care 2009;32:1542-6. 
75. Kliewer SA, Mangelsdorf DJ. Fibroblast growth factor 21: 
from pharmacology to physiology. Am J Clin Nutr 2010; 
91:254S-7S. 
76. Carpéné C, Dray C, Attané C, et al. Expanding role 
for the apelin/APJ system in physiopathology. J Physiol 
Biochem 2007;63:359-73. 
77. Quazi R, Palaniswamy C, Frishman WH. The emerging 
role of apelin in cardiovascular disease and health. Cardiol 
Rev 2009;17:283-86. 
78. Görgens SW, Raschke S, Holven KB, et al. Regulation 
of follistatin-like protein 1 expression and secretion 
in primary human skeletal muscle cells. Arch Physiol 
Biochem 2013;119:75-80. 
79. Mancia G, Fagard R, Narkiewicz K, et al. Task 
Force Members. 2013 ESH/ESC Guidelines for the 
management of arterial hypertension: the Task Force 
for the management of arterial hypertension of the 
European Society of Hypertension (ESH) and of the 
European Society of Cardiology (ESC). J Hypertens 
2013;31:1281-357. 
80. Fagard RH, Cornelissen VA. Effect of exercise on blood 
pressure control in hypertensive patients. Eur J Cardiovasc 
Prev Rehabil 2007;14:12-7. 
81. Lee LL, Watson MC, Mulvaney CA, et al. The effect 
of walking intervention on blood pressure control: a 
systematic review. Int J Nurs Stud 2010;47:1545-61. 
82. Cornelissen VA, Buys R, Smart NA. Endurance exercise 
beneficially affects ambulatory blood pressure: a systematic 
review and meta-analysis. J Hypertens 2013;31:639-48. 
83. Cornelissen VA, Smart NA. Exercise training for blood 
pressure: a systematic review and meta-analysis. J Am 
Heart Assoc 2013;2:e004473. 
84. Cornelissen VA, Goetschalckx K, Verheyden B, et al. 
Effect of endurance training on blood pressure regulation, 
biomarkers and the heart in subjects at a higher age. Scand 
J Med Sci Sports 2011;21:526-34. 
85. Cornelissen VA, Fagard RH. Effects of endurance 
training on blood pressure, blood pressure-regulating 
Di Raimondo et al. Myokines and cardiac rehabilitation
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2017;5(15):300atm.amegroups.com
Page 12 of 14
mechanisms, and cardiovascular risk factors. 
Hypertension 2005;46:667-75. 
86. Di Raimondo D, Tuttolomondo A, Miceli S, et al. Aerobic 
physical activity based on fast walking does not alter blood 
pressure values in non-dipper essential hypertensives. Int 
Angiol 2012;31:142-9. 
87. Fagard RH, Tipton CM. Physical activity, fitness and 
hypertension. In: Bouchard C, Shephard RJ, Stephens T. 
editors. Physical Activity, Fitness and Health. Champaign, 
Ill: Human Kinetics,1994:633-55.
88. Kohno K, Matsuoka H, Takenaka K, et al. Renal depressor 
mechanisms of physical training in patients with essential 
hypertension. Am J Hypertens 1997;10:859-68. 
89. Guyton AC. Kidneys and fluids in pressure regulation. 
Hypertension 1992;19:I2-I8. 
90. Higashi Y, Sasaki S, Kurisu S, et al. Regular aerobic 
exercise augments endothelium-dependent vascular 
relaxation in normotensive as well as hypertensive subjects: 
role of endothelium-derived nitric oxide. Circulation 
1999;100:1194-202. 
91. Chen HI, Chiang IP. Chronic exercise decreases adrenergic 
agonist-induced vasoconstriction in spontaneously 
hypertensive rats. Am J Physiol 1996;271:H977-83. 
92. Jonsdottir IH, Jungersten L, Johansson C, et al. Increase 
in nitric oxide formation after chronic voluntary exercise 
in spontaneously hypertensive rats. Acta Physiol Scand 
1998;162:149-53. 
93. Pescatello LS, Franklin BA, Fabard R, et al. American 
College of Sports Medicine position stand. Exercise and 
hypertension. Med Sci Sports Exerc 2004;36:533-53. 
94. Hagberg JM, Ferrell RE, Dengel DR, et al. Exercise 
training-induced blood pressure and plasma lipid 
improvements in hypertensives may be genotype 
dependent. Hypertension 1999;34:18-23. 
95. Tuttolomondo A, Casuccio A, Della Corte V, et al. 
Endothelial function and arterial stiffness indexes in 
subjects with acute ischemic stroke: Relationship with 
TOAST subtype. Atherosclerosis 2017;256:94-9. 
96. Della Corte V, Tuttolomondo A, Pecoraro R, et al. 
Inflammation, Endothelial Dysfunction and Arterial 
Stiffness as Therapeutic Targets in Cardiovascular 
Medicine. Curr Pharm Des 2016;22:4658-68. 
97. Tuttolomondo A, Pecoraro R, Casuccio A, et al. Peripheral 
frequency of CD4+ CD28- cells in acute ischemic stroke: 
relationship with stroke subtype and severity markers. 
Medicine (Baltimore) 2015;94:e813. 
98. Tuttolomondo A, Pecoraro R, Di Raimondo D, et al. 
Immune-inflammatory markers and arterial stiffness 
indexes in subjects with acute ischemic stroke with and 
without metabolic syndrome. Diabetol Metab Syndr 
2014;6:28. 
99. Tuttolomondo A, Pecoraro R, Di Raimondo D, et 
al. Stroke subtypes and their possible implication in 
stroke prevention drug strategies. Curr Vasc Pharmacol 
2013;11:824-37. 
100. Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. 
Inflammation in ischemic stroke subtypes. Curr Pharm 
Des 2012;18:4289-310. 
101. Tuttolomondo A, Pedone C, Pinto A, et al. Predictors of 
outcome in acute ischemic cerebrovascular syndromes: 
The GIFA study. Int J Cardiol 2008;125:391-6. 
102. Knaepen K, Goekint M, Heyman EM, et al. 
Neuroplasticity: exercise-induced response of peripheral 
brain-derived neurotrophic factor: a systematic review 
of experimental studies in human subjects. Sports Med 
2010;40:765-801. 
103. Seifert T, Brassard P, Wissenberg M, et al. Endurance 
training enhances BDNF release from the human 
brain. Am J Physiol Regul Integr Comp Physiol 
2010;298:R372-7. 
104. Gold SM, Schulz KH, Hartmann S, et al. Basal serum 
levels and reactivity of nerve growth factor and brain-
derived neurotrophic factor to standardized acute exercise 
in multiple sclerosis and controls. J Neuroimmunol 
2003;138:99-105. 
105. Rasmussen P, Brassard P, Adser H, et al. Evidence for a 
release of brain-derived neurotrophic factor from the brain 
during exercise. Exp Physiol 2009;94:1062-9. 
106. Ploughman M, Austin MW, Glynn L, et al. The effects of 
poststroke aerobic exercise on neuroplasticity: a systematic 
review of animal and clinical studies. Transl Stroke Res 
2015;6:13-28. 
107. Austin MW, Ploughman M, Glynn L, et al. Aerobic 
exercise effects on neuroprotection and brain repair 
following stroke: a systematic review and perspective. 
Neurosci Res 2014;87:8-15. 
108. Mang CS, Campbell KL, Ross CJ, et al. Promoting 
neuroplasticity for motor rehabilitation after stroke: 
considering the effects of aerobic exercise and genetic 
variation on brain-derived neurotrophic factor. Phys Ther 
2013;93:1707-16. 
109. Okazaki H, Beppu H, Mizutani K, et al. Changes in serum 
growth factors in stroke rehabilitation patients and their 
relation to hemiparesis improvement. J Stroke Cerebrovasc 
Dis 2014;23:1703-8. 
110. Pasarica D, Gheorghiu M, Topârceanu F, et al. 
Annals of Translational Medicine, Vol 5, No 15 August 2017 Page 13 of 14
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2017;5(15):300atm.amegroups.com
Neurotrophin-3, TNF-alpha and IL-6 relations in serum 
and cerebrospinal fluid of ischemic stroke patients. Roum 
Arch Microbiol Immunol 2005;64:27-33. 
111. Pikula A, Beiser AS, Chen TC, et al Serum brain-derived 
neurotrophic factor and vascular endothelial growth factor 
levels are associated with risk of stroke and vascular brain 
injury: Framingham Study. Stroke 2013;44:2768-75. 
112. Kang SS, Keasey MP, Arnold SA, et al. Endogenous 
CNTF mediates stroke-induced adult CNS neurogenesis 
in mice. Neurobiol Dis 2013;49:68-78. 
113. Xiao Y, Liu L, Xu A, et al. Serum fibroblast growth 
factor 21 levels are related to subclinical atherosclerosis 
in patients with type 2 diabetes. Cardiovasc Diabetol 
2015;14:72. 
114. Belardinelli R, Georgiou D, Cianci G, et al. Randomized, 
controlled trial of long-term moderate exercise training in 
chronic heart failure: effects on functional capacity, quality 
of life, and clinical outcome. Circulation 1999;99:1173-82. 
115. He J, Ogden LG, Bazzano LA, et al. Risk factors for 
congestive heart failure in US men and women: NHANES 
I epidemiologic follow-up study. Arch Intern Med 
2001;161:996-1002. 
116. Lloyd-Williams F, Mair FS, Leitner M. Exercise training 
and heart failure: a systematic review of current evidence. 
Br J Gen Pract 2002:52:47-55. 
117. Rees K, Taylor RS, Singh S, et al. Exercise based 
rehabilitation for heart failure. Cochrane Database Syst 
Rev 2004;(3):CD003331. 
118. Piepoli MF, Davos C, Francis DP, et al. Exercise training 
meta-analysis of trials in patients with chronic heart failure 
(ExTraMATCH). BMJ 2004;328:189. 
119. Tavazzi L, Giannuzzi P. Physical training as a 
therapeutic measure in chronic heart failure: time for 
recommendations. Heart 2001;86:7-11. 
120. Volterrani M, Clark AL, Ludman PF, et al. Predictors 
of exercise capacity in chronic heart failure. Eur Heart J 
1994;15:801-9. 
121. Franciosa JA, Park M, Levine TB. Lack of correlation 
between exercise capacity and indexes of resting left 
ventricular performance in heart failure. Am J Cardiol 
1981;47:33-9. 
122. Minotti JR, Christoph I, Oka R, et al. Impaired skeletal 
muscle function in patients with congestive heart failure. 
Relationship to systemic exercise performance. J Clin 
Invest 1991;88:2077-82. 
123. Sullivan MJ, Green HJ, Cobb FR. Altered skeletal muscle 
metabolic response to exercise in chronic heart failure. 
Relation to skeletal muscle aerobic enzyme activity. 
Circulation 1991;84:1597-607. 
124. Panagopoulou N, Karatzanos E, Dimopoulos S, et al. 
Exercise training improves characteristics of exercise 
oscillatory ventilation in chronic heart failure. Eur J Prev 
Cardiol 2017;24:825-32. 
125. Belardinelli R, Georgiou D, Ginzton L, et al. Effects 
of moderate exercise training on thallium uptake 
and contractile response to low-dose dobutamine of 
dysfunctional myocardium in patients with ischemic 
cardiomyopathy. Circulation 1998;97:553-61. 
126. Shyu KG, Lu MJ, Wang BW, et al. Myostatin expression 
in ventricular myocardium in a rat model of volume-
overload heart failure. Eur J Clin Invest 2006;36:713-9. 
127. Sharma M, Kambadur R, Matthews KG, et al. Myostatin, 
a transforming growth factor-beta superfamily member, 
is expressed in heart muscle and is upregulated in 
cardiomyocytesafter infarct. J Cell Physiol 1999;180:1-9. 
128. Ichige MH, Santos CR, Jordão CP, et al. Exercise 
training preserves vagal preganglionic neurones and 
restores parasympathetic tonus in heart failure. J Physiol 
2016;594:6241-54. 
129. Zucker IH, Schultz HD, Patel KP, et al. Modulation 
of angiotensin II signaling following exercise training 
in heart failure. Am J Physiol Heart Circ Physiol 
2015;308:H781-91. 
130. Berdeaux A, Ghaleh B, Dubois-Randé JL, et al. Role of 
vascular endothelium in exercise-induced dilation of large 
epicardial coronary arteries in conscious dogs. Circulation 
1994;89:2799-808. 
131. Niebauer J, Cooke JP. Cardiovascular effects of exercise: 
role of endothelial shear stress. J Am Coll Cardiol 
1996;28:1652-60. 
132. Li H, Förstermann U. Nitric oxide in the pathogenesis of 
vascular disease. J Pathol 2000;190:244-54. 
133. Kingwell BA. Nitric oxide-mediated metabolic regulation 
during exercise: effects of training in health and 
cardiovascular disease. FASEB J 2000;14:1685-96. 
134. Cooke JP, Tsao PS. Go with the flow. Circulation 
2001;103:2773-5 
135. Nishida K, Harrison DG, Navas JP, et al. Molecular 
cloning and characterization of the constitutive bovine 
aortic endothelial cell nitric oxide synthase. J Clin Invest 
1992;90:2092-6 
136. Taylor RS, Brown A, Ebrahim S, et al. Exercise based 
rehabilitation for patients with coronary heart disease: 
systematic review and meta-analysis of randomized 
controlled trials. Am J Med 2004;116:682-92. 
137. Milani RV, Lavie CJ. Prevalence and profile of metabolic 
Di Raimondo et al. Myokines and cardiac rehabilitation
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2017;5(15):300atm.amegroups.com
Page 14 of 14
syndrome in patients following acute coronary events 
and effects of therapeutic lifestyle change with cardiac 
rehabilitation. Am J Cardiol 2003;92:50-4. 
138. Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive 
protein through cardiac rehabilitation and exercise 
training. J Am Coll Cardiol 2004;43:1056-61. 
139. Caulin-Glaser T, Falko J, Hindman L, et al. Cardiac 
rehabilitation is associated with an improvement in 
C-reactive protein levels in both men and women 
with cardiovascular disease. J Cardiopulm Rehabil 
2005;25:332-6. 
140. Walther C, Möbius-Winkler S, Linke A, et al. Regular 
exercise training compared with percutaneous intervention 
leads to a reduction of inflammatory markers and 
cardiovascular events in patients with coronary artery 
disease. Eur J Cardiovasc Prev Rehabil 2008;15:107-12. 
141. Plüss CE, Karlsson MR, Wallen NH, et al. Effects 
of an expanded cardiac rehabilitation programme in 
patients treated for an acute myocardial infarction or a 
coronary artery by-pass graft operation. Clin Rehabil 
2008;22:306-18. 
142. Goldhammer E, Tanchilevitch A, Maor I, et al. Exercise 
training modulates cytokines activity in coronary heart 
disease patients. Int J Cardiol 2005;100:93-9. 
143. Schumacher A, Peersen K, Sommervoll L, et al. Physical 
performance is associated with markers of vascular 
inflammation in patients with coronary heart disease. Eur J 
Cardiovasc Prev Rehabil 2006;13:356-62.
144. Astengo M, Dahl A, Karlsson T, et al. Physical training 
after percutaneous coronary intervention in patients with 
stable angina: effects on working capacity, metabolism, and 
markers of inflammation. Eur J Cardiovasc Prev Rehabil 
2010;17:349-54.
145. Cesari F, Sofi F, Caporale R, et al. Relationship 
between exercise capacity, endothelial progenitor cells 
and cytochemokines in patients undergoing cardiac 
rehabilitation. Thromb Haemost 2009;101:521-6.
146. Bruun JM, Helge JW, Richelsen B, et al. Diet and 
exercise reduce lowgrade inflammation and macrophage 
infiltration in adipose tissue but not in skeletal muscle in 
severely obese subjects. Am J Physiol Endocrinol Metab 
2006;290:E961-7.
147. Castillero E, Akashi H, Wang C, et al. Cardiac myostatin 
upregulation occurs immediately after myocardial ischemia 
and is involved in skeletal muscle activation of atrophy. 
Biochem Biophys Res Commun 2015;457:106-11. 
148. Lee DC, Pate RR, Lavie CJ, et al. Leisure-time running 
reduces all-cause and cardiovascular mortality risk. J Am 
Coll Cardiol 2014;64:472-81. 
149. Wen CP, Wai JP, Tsai MK, et al. Minimum amount of 
physical activity for reduced mortality and extended 
life expectancy: a prospective cohort study. Lancet 
2011;378:1244-53. 
150. Sanchis-Gomar F, Pareja-Galeano H, Mayero S, et al. 
New molecular targets and lifestyle interventions to delay 
aging sarcopenia. Front Aging Neurosci 2014;6:156. 
151. Sanchis-Gomar F, Pareja-Galeano H, Santos-Lozano 
A, et al. A preliminary candidate approach identifies 
the combination of chemerin, fetuin-A, and fibroblast 
growth factors 19 and 21 as a potential biomarker panel of 
successful aging. Age (Dordr) 2015;37:9776. 
152. Sanchis-Gomar F, Perez-Quilis C, Lucia A. Overexpressing 
FSTL1 for Heart Repair. Trends Mol Med 2016;22:353-4. 
153. Fischer CP. Interleukin-6 in acute exercise and training: 
what is the biological relevance? Exerc Immunol Rev 
2006;12:6-33. 
154. Miyashita M, Burns SF, Stensel DJ. Accumulating short 
bouts ofbrisk walking reduces postprandial plasma 
triacylglycerol concentrations and resting blood pressure 
in healthy young men. Am J Clin Nutr 2008;88:1225-31. 
155. Murphy M, Nevill A, Neville C, et al. Accumulating brisk 
walking for fitness, cardiovascular risk, and psychological 
health. Med Sci Sports Exerc 2002;34:1468-74. 
156. Markovitch D, Tyrrell RM, Thompson D. Acute moderate 
intensity exercise in middle-aged men has neither an anti- 
nor proinflammatory effect. J Appl Physiol 2008;105:260-5. 
Cite this article as: Di Raimondo D, Miceli G, Musiari G, 
Tuttolomondo A, Pinto A. New insights about the putative 
role of myokines in the context of cardiac rehabilitation 
and secondary cardiovascular prevention. Ann Transl Med 
2017;5(15):300. doi: 10.21037/atm.2017.07.30
